Virtual Library
Start Your Search
Abdolali Shahrasbi
Author of
-
+
P3.01 - Advanced NSCLC (ID 621)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P3.01-047 - Erlotinib Induced Ectropion Followed by Papulo-Erythemato Skin Rash (ID 9559)
09:30 - 09:30 | Presenting Author(s): Abdolali Shahrasbi
- Abstract
Background:
Erlotinib is a thyrosine kinase inhibitor which prevents epidermal growth factor receptor(EGFR) by blocking intracellular phosphorylation. Various cutaneous side effects have been associated with EGFR inhibitors. We present a case with ectropion and conjunctivitis followed by erythemato papulopustular skin rash.
Method:
Figure 1A 72 year old male who has suffered from non small cell carcinoma (adenocarcinoma)of lung stage IV since one year ago came to our clinic with bilateral ectropion and conjunctivitis. He has received erlotinib 150 mg/d since three to four months ago.
Result:
Figure 1We prescribed supportive care and symptomatic treatment and discontinued erlotinib for one week due to the severity of eye disease. It resolved gradually after two weeks but erythemato papulr rash appeared
Conclusion:
EGFR inhibitors are one of the most important treatment modalities among patients with lung adenocarcinoma.Cutaneous side effects of these agents are reported frequently. Eye disease including ectropion is a rare adverse effect of these factors. We describe this case to consider the newly diagnosed eye edverse effect of this important agents.
